Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2021 Jun 22;143(25):2508-2510.
doi: 10.1161/CIRCULATIONAHA.121.054785. Epub 2021 Jun 7.

Reduction in Kawasaki Disease After Nonpharmaceutical Interventions in the COVID-19 Era: A Nationwide Observational Study in Korea

Ji-Man Kang #  1   2 , Young-Eun Kim #  3 , Kyungmin Huh  4 , Jinwook Hong  5 , Dong Wook Kim  3 , Min Young Kim  1   2 , Se Yong Jung  6 , Jong-Hun Kim  7 , Jaehun Jung  5   8 , Jong Gyun Ahn  1   2
Affiliations
Observational Study

Reduction in Kawasaki Disease After Nonpharmaceutical Interventions in the COVID-19 Era: A Nationwide Observational Study in Korea

Ji-Man Kang et al. Circulation. .
No abstract available

Keywords: COVID-19; Kawasaki disease; Republic of Korea; incidence; mucocutaneous lymph node syndrome; physical distancing.

PubMed Disclaimer

Figures

Figure.
Figure.
Kawasaki disease (KD) incidence in Korea. A, Yearly incidence of KD from 2010 to 2020. The red line denotes the age-specific incidence of KD, and the blue line denotes the age-specific incidence of intravenous immunoglobulin (IVIg)–resistant KD. The dotted line represents February 2020, when nonpharmaceutical interventions (NPIs) were implemented in Korea owing to coronavirus disease 2019 (COVID-19). B through E, Monthly incidence of KD and incidence predicted by an autoregressive integrated moving average model. The thick red line denotes the observed incidence during the NPI period, the thick blue line denotes the predicted incidence in the NPI period, and blue shades represent 80% and 95% CIs of the predicted incidence in the NPI period.
See this image and copyright information in PMC

References

    1. McCrindle BW, Rowley AH, Newburger JW, Burns JC, Bolger AF, Gewitz M, Baker AL, Jackson MA, Takahashi M, Shah PB, et al. ; American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; Council on Cardiovascular Surgery and Anesthesia; and Council on Epidemiology and Prevention. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation. 2017;135:e927–e999. doi: 10.1161/CIR.0000000000000484 - PubMed
    1. Huh K, Jung J, Hong J, Kim M, Ahn JG, Kim JH, Kang JM. Impact of nonpharmaceutical interventions on the incidence of respiratory infections during the coronavirus disease 2019 (COVID-19) outbreak in Korea: a nationwide surveillance study. Clin Infect Dis. 2021;72:e184–e191. doi: 10.1093/cid/ciaa1682 - PMC - PubMed
    1. Burns JC, Cayan DR, Tong G, Bainto EV, Turner CL, Shike H, Kawasaki T, Nakamura Y, Yashiro M, Yanagawa H. Seasonality and temporal clustering of Kawasaki syndrome. Epidemiology. 2005;16:220–225. doi: 10.1097/01.ede.0000152901.06689.d4 - PMC - PubMed
    1. Rodó X, Curcoll R, Robinson M, Ballester J, Burns JC, Cayan DR, Lipkin WI, Williams BL, Couto-Rodriguez M, Nakamura Y, et al. . Tropospheric winds from northeastern China carry the etiologic agent of Kawasaki disease from its source to Japan. Proc Natl Acad Sci U S A. 2014;111:7952–7957. doi: 10.1073/pnas.1400380111 - PMC - PubMed
    1. Elakabawi K, Lin J, Jiao F, Guo N, Yuan Z. Kawasaki disease: global burden and genetic background. Cardiol Res. 2020;11:9–14. doi: 10.14740/cr993 - PMC - PubMed